Notably, 2024 produced the second-highest number of Home Infusion and Specialty Rx deals over the past decade
While buyers remain selectively interested in the most attractive specialty and institutional Rx providers, home infusion therapy, with its comparatively superior margins, is leading a resurgence in acquisition interest in Home Infusion and Specialty Rx.
Combined Deal Value
The total value of all of the deals closed by The Braff Group in the Home Infusion and Specialty Rx sector.
Total Deals Made
The combined number of deals closed by The Braff Group in the Home Infusion and Specialty Rx sector.
Deal Valuation Comps
The combined number of deals closed by The Braff Group in the Home Infusion and Specialty Rx sector.
This interactive module keeps you informed with annual and quarterly performance graphs, giving you a clear view of key trends, valuation movements, and market dynamics.